Premium
Severe persistent bone marrow failure following therapy with 2‐chlorodeoxyadenosine for relapsing juvenile xanthogranuloma of the brain
Author(s) -
Yamada Kayo,
Yasui Masahiro,
Sawada Akihisa,
Inoue Masami,
Nakayama Masahiro,
Kawa Keisei
Publication year - 2012
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.23087
Subject(s) - medicine , juvenile xanthogranuloma , langerhans cell histiocytosis , bone marrow , refractory (planetary science) , histiocytosis , salvage therapy , cladribine , bone marrow failure , lesion , chemotherapy , surgery , pathology , haematopoiesis , disease , histiocyte , stem cell , physics , astrobiology , biology , genetics
2‐Chlorodeoxyadenosine (2‐CdA) has been successfully used in children to treat refractory Langerhans cell histiocytosis and juvenile xanthogranuloma (JXG) as salvage therapy. Although 2‐CdA is generally well‐tolerated, with temporary myelosuppression as the primary dose‐limiting toxicity, prolonged myelosuppressive, and immunosuppressive effects have been reported. We describe an adolescent patient with refractory multiple central nervous system JXG, with the lesion size markedly reduced after treatment with 2‐CdA. However, severe transfusion‐dependent bone marrow failure developed after five courses of 2‐CdA. He underwent successful bone marrow transplantation from his HLA compatible sister with reduced intensity conditioning. Pediatr Blood Cancer 2012; 58: 300–302. © 2011 Wiley Periodicals, Inc.